• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Emerg Infect Dis . Increased SARS-CoV-2 Testing Capacity with Pooled Saliva Samples

tetano

Editor, Senior Moderator
Emerg Infect Dis


. 2021 Apr;27(4).
doi: 10.3201/eid2704.204200.
Increased SARS-CoV-2 Testing Capacity with Pooled Saliva Samples

Anne E Watkins, Eli P Fenichel, Daniel M Weinberger, Chantal B F Vogels, Doug E Brackney, Arnau Casanovas-Massana, Melissa Campbell, John Fournier, Santos Bermejo, Rupak Datta, Charles S Dela Cruz, Shelli F Farhadian, Akiko Iwasaki, Albert I Ko, Nathan D Grubaugh, Anne L Wyllie, Yale IMPACT Research Team2

Abstract

We analyzed feasibility of pooling saliva samples for severe acute respiratory syndrome coronavirus 2 testing and found that sensitivity decreased according to pool size: 5 samples/pool, 7.4% reduction; 10 samples/pool, 11.1%; and 20 samples/pool, 14.8%. When virus prevalence is >2.6%, pools of 5 require fewer tests; when <0.6%, pools of 20 support screening strategies.

Keywords: 2019 novel coronavirus disease; COVID-19; SARS-CoV-2; coronavirus disease; diagnostics; respiratory infections; saliva; screening; severe acute respiratory syndrome coronavirus 2; viruses; zoonoses.
 
Back
Top Bottom